SITAGLIVAC M 50/500

SITAGLIVAC M 50/500 is a fixed-dose combination of Sitagliptin (50 mg) and Metformin (500 mg), designed for the effective management of Type 2 Diabetes Mellitus (T2DM).

• Sitagliptin (a DPP-4 inhibitor) works by increasing the levels of incretin hormones, which help stimulate insulin release and reduce glucose production in the liver.

• Metformin (a biguanide) decreases glucose absorption from the intestine and lowers glucose production in the liver, while improving insulin sensitivity.

Together, they provide better glycemic control, help lower HbA1c levels, and reduce the risk of long-term diabetes complications.

Key Benefits:

• Dual-action therapy for Type 2 Diabetes

• Improves insulin secretion and sensitivity

• Reduces glucose production in the liver

• Helps maintain stable blood sugar levels throughout the day

• Effective in patients not controlled by diet, exercise, or single therapy alone

• Low risk of weight gain compared to other diabetes medicines